-
1Academic Journal
Συγγραφείς: Z. R. Aisanov, S. N. Avdeev, A. S. Belevskiy, A. A. Vizel', A. V. Emel'yanov, G. L. Ignatova, O. M. Kurbacheva, I. V. Leshchenko, N. M. Nenasheva, S. I. Ovcharenko, A. I. Sinopal'nikov, O. N. Titova, З. Р. Айсанов, С. Н. Авдеев, А. С. Белевский, А. A. Визель, А. В. Емельянов, Г. Л. Игнатова, О. М. Курбачева, И. В. Лещенко, Н. М. Ненашева, С. И. Овчаренко, А. И. Синопальников, О. Н. Титова
Συνεισφορές: The Expert Council of the Russian Respiratory Society was held with the support of Novartis Pharma LLC. The representatives of Novartis Pharma LLC did not participate in the writing of this article, are not responsible for the content of the article, and are not responsible for any possible financial or other agreements with any third parties related to this article. The opinion of Novartis Pharma LLC may differ from the opinion of the author of the article and the editorial board., Совет экспертов Российского респираторного общества проведен при поддержке Общества с ограниченной ответственностью «Новартис Фарма». В написании настоящей статьи представители Общества с ограниченной ответственностью «Новартис Фарма» не принимали участия, не несут ответственности за содержание статьи и любые возможные, относящиеся к данной статье договоренности либо финансовые соглашения с любыми третьими лицами. Мнение Общества с ограниченной ответственностью «Новартис Фарма» может отличаться от мнения авторов статьи и редакции.
Πηγή: PULMONOLOGIYA; Том 31, № 1 (2021); 66-74 ; Пульмонология; Том 31, № 1 (2021); 66-74 ; 2541-9617 ; 0869-0189
Θεματικοί όροι: ARGON, control, exacerbation, indacaterol, glycopyrronium, mometasone, Breezhaler®, long-acting β 2 -agonist/inhaled corticosteroid, long-acting anticholinergics, IRIDIUM, контроль, обострение, индакатерола ацетат, гликопирроний, мометазона фуроат, Бризхалер®, длительно действующие β 2 -агонисты / ингаляционные глюкокортикостероиды, длительно действующие антихолинергические препараты
Περιγραφή αρχείου: application/pdf
Relation: https://journal.pulmonology.ru/pulm/article/view/2268/1818; Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990—2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir. Med. 2017; 5 (9): 691—706. DOI:10.1016/S2213-2600(17)30293-X.; Chuchalin A., Khaltaev N., Antonov N. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9 (1): 963—974. DOI:10.2147/COPD.S67283.; Global Initiative for Asthma. 2020 GINA Report, Global Strategy for Asthma Management and Prevention. Available at: https://ginasthma.org/gina-reports/ [Accessed: July 17, 2020].; Stanford R.H., Gilsenan A.W., Ziemiecki R. et al. Predictors of uncontrolled asthma in adult and pediatric patients: Analysis of the Asthma Control Characteristics and Prevalence Survey Studies (ACCESS). J. Asthma. 2010; 47 (3): 257—262. DOI:10.3109/02770900903584019.; Buhl R., Heaney L.G., Loefroth E. et al. One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting p2-agonist in UK primary care settings. Respir. Med. 2020; 162: 105859. DOI:10.1016/j.rmed.2019.105859.; Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 2004; 170 (8): 836—844. DOI:10.1164/rccm.200401-033OC.; Price D., Fromer L., Kaplan A. et al. Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? NPJ Prim. Care Respir. Med. 2014; 24: 14023. DOI:10.1038/npjpcrm.2014.23.; Meurs H., Dekkers B.G., Maarsingh H. et al. Muscarinic receptors on airway mesenchymal cells: Novel findings for an ancient target. Pulm. Pharmacol. Ther. 2013; 26 (1): 145—155. DOI:10.1016/j.pupt.2012.07.003.; Alagha K., Palot A., Sofalvi T. et al. Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Ther. Adv. Chronic. Dis. 2014; 5 (2): 85—98. DOI:10.1177/2040622313518227.; Kerstjens H.A.M., Engel M., Dahl R. et al. Tiotropium in asthma poorly controlled with standard combination therapy. N. Engl. J. Med. 2012; 367 (13): 1198—207. DOI:10.1056/NEJMoa1208606.; Kew K.M., Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst. Rev. 2015; (5): CD011721. DOI:10.1002/14651858.CD011721.; Kerstjens H.A.M., Maspero J., Chapman K.R. et al. Once-daily, single-inhaler mometasone—indacaterol—glycopyrronium versus mometasone—indacaterol or twice-daily fluti-casone—salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir. Med. 2020; 8 (10): 1000—1012. DOI:10.1016/S2213-2600(20)30190-9.; Gessner C., Kornmann O., Maspero J. et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, phase IIIb, non-inferiority study (ARGON). Respir. Med. 2020; 170: 106021. DOI:10.1016/j.rmed.2020.106021.; Papi A., Humbert M., Kostikas K. et al. Medium-dose inda-caterol/glycopyrronium/mometasone furoate fixed-dose combination improves lung function compared with high-dose indacaterol/mometasone furoate and salmeterol/fluti-casone and reduces exacerbation rates versus high-dose sal-meterol/fluticasone in moderate-to-severe asthma: The IRIDIUM study. Am. J. Respir. Crit. Care Med. 2020; 201: A3008. DOI:10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A3008.; Российское респираторное общество. Бронхиальная астма: Федеральные клинические рекомендации. 2019. Доступно на: http://spulmo.ru/upload/kr_bronhastma_2019.pdf [Дата обращения 17.07.20].; Derendorf H., Nave R., Drollmann A. et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur. Respir. J. 2006; 28 (5): 1042— 1050. DOI:10.1183/09031936.00074905.; Cowie R.L., Giembycz M.A., Leigh R. Mometasone furoate: an inhaled glucocorticoid for the management of asthma in adults and children. Expert Opin. Pharmacother. 2009; 10 (12): 2009—2014. DOI:10.1517/14656560903078428.; Donohue J.F., Betts K.A., Du E.X. et al. Comparative efficacy of long-acting p2-agonists as monotherapy for chronic obstructive pulmonary disease: a network metaanalysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 367381. DOI:10.2147/COPD.S119908.; Blais C.M., Davis B.E., Cockcroft D.W. The effect of gly-copyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study. Respir. Res. 2017; 18 (1): 146. DOI:10.1186/s12931-017-0628-4.; Sanders M.J. Guiding inspiratory flow: development of the In-Check DIAL G16, a tool for improving inhaler technique. Pulm. Med. 2017; 2017: 1495867. DOI:10.1155/2017/1495867.; Altman P., Wehbe L., Dederichs J. et al. Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial. BMC Pulm. Med. 2018; 18 (1): 100. DOI:10.1186/s12890-018-0662-0.; Dolovich M.A., Kuttler A., Dimke T.J., Usmani O.S. Biophysical model to predict lung delivery from a dual bronchodilator dry-powder inhaler. Int. J. Pharm. 2019; 1: 100018. DOI:10.1016/j.ijpx.2019.100018.; Sanduzzi A., Balbo P., Candoli P. et al. COPD: adherence to therapy. Multidiscip. Respir. Med. 2014; 9: 60. DOI:10.1186/2049-6958-9-60.; Price D., Keininger D.L., Viswanad B. et al. Factors associated with appropriate inhaler use in patients with COPD -lessons from the REAL survey [Erratum]. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 2253-2254. DOI:10.2147/COPD.S178410.; Визель А.А., Резяпова А.И., Визель И.Ю., Амиров Н.Б. К поиску «идеального» средства доставки лекарственных веществ при обструктивных заболеваниях органов дыхания: наблюдательное исследование в сравнении с данными литературы. Вестник современной клинической медицины. 2020; 13 (2): 22-30. DOI:10.20969/VSKM.2020.13(2).22-30.; Vaidya S.S., Khindri S., Robinson J. et al. Pharmacokinetics (PK) of single doses of mometasone furoate (MF) delivered via the Breezhaler® (BH) and Twisthaler® (TH) devices in healthy subjects. Eur. Respir. J. 2012; 40 (Suppl. 56): 2145. Available at: https://erj.ersjournals.com/content/erj/40/Suppl_56/P2145.full.pdf; Buhl R., Tanase A.M., Hosoe M. et al. A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma. Pulm. Pharmacol. Ther. 2020; 62: 101919. DOI:10.1016/j.pupt.2020.101919.; Saini S.D., Schoenfeld P., Kaulback K., Dubinsky M.C. Effect of medication dosing frequency on adherence in chronic diseases. Am. J. Manag. Care. 2009; 15 (6): e22-33.; Beier J., Watz H., Scholz V. The efficacy of the combination indacaterol/glycopyrronium/mometasone furoate is independent of time of dosing in patients with asthma. Am. J. Respir. Crit. Care Med. 2019; 199: A1277. DOI:10.1164/ajrc-cm-conference.2019.199.1_MeetingAbstracts.A1277.; Virchow J.C., Kuna P., Paggiaro P. et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019; 394 (10210): 1737-1749. DOI:10.1016/S0140-6736(19)32215-9.; Lee L.A., Bailes Z., Barnes N. et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir. Med. 2021; 9 (1): 69-84. DOI:10.1016/S2213-2600(20)30389-1.; https://journal.pulmonology.ru/pulm/article/view/2268